Rachel Legmann

Senior Director of Technology, Gene Therapy at Repligen

Speaker, Moderator

Rachel has more than 25 years of experience in the field of scalable biologics and gene therapy manufacturing of therapeutic products, viral vectors, and proteins for gene therapy and biologics. She completed her PhD in Food Engineering and Biotechnology at the Technion-Israel Institute of Technology, Haifa, Israel. Rachel joined Repligen, Waltham, MA, USA in 2021 as a subject matter expert, leading the global gene therapy organization and helping customers achieve their technical and operational objectives in their manufacturing of vector-based therapeutics and vaccines, with a focus on gene therapy processes including upstream, downstream, analytics, and scalability. In addition to supporting global custom­ers and building high level networks, Rachel is supporting various internal cross-functional activities and external collaborations. Prior to joining Repligen, Rachel held several scien­tific and leadership roles at the Department of Microbiology and Molecular Genetics at Harvard Medical School, CRO SBH Sciences, Seahorse Biosciences (part of Agilent), CDMO Goodwin Biotechnology, and Pall Corp part of Danaher.